**Supplementary Tables**

Table 1: Surveys and outlets sampled

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Survey country/province (country code)** | **World Bank income group 2016** | **Government procurement prices collected** | **No. public hospitals sampled** | **No. private retail pharmacies sampled** | **No. private hospitals/**  **clinics sampled** | **At least one analogue on national**  **EML** |
| Ethiopia (ET) | Low | Yes | 3 | 15 | 3 | No |
| Mali (ML) | Low | Yes | 3 | 14 | 3 | No |
| Uganda (UG) | Low | Yes | 3 (free) | 15 | 3 | No |
| Kenya (KE) | Lower-middle | No | 3 | 15 | 3 | No |
| Ghana (GH) | Lower-middle | Yes | 3 | 15 | 3 | Yes |
| India, Haryana (IH) | Lower-middle | Yes | 3 (free) | 15 | 3 | No |
| India, Madhya Pradesh (IP) | Lower-middle | Yes | 3 (free) | 15 | 3 | No |
| Pakistan (PK)\* | Lower-middle | Yes | 4 (free) | 20 | 4 | No |
| Kyrgyzstan (KG) | Lower-middle | Yes | 4 (free) | 15 | 3 | Yes |
| Indonesia (ID) | Lower-middle | Yes | 4 | 15 | 4 | Yes |
| Jordan (JO) | Upper-middle | Yes | 3 | 15 | 1 | Yes |
| Russia, Kazan (RU) | Upper-middle | Yes | 11 (free)\*\* | 10 | - | Yes |
| China, Hubei (CB) | Upper-middle | Yes | 3 | 15 | 2 | Yes |
| China, Shaanxi (CS) | Upper-middle | Yes | 3 | 15 | 3 | Yes |
| Brazil (BR) | Upper-middle | Yes | 7 (free)\*\*\* | 15 | 1 | No |
| **Total:** | | | **60** | **224** | **39** |  |

*Free = insulin supplied free-of-charge; \*data were collected in Islamabad and Lahore then aggregated \*\*Insulin free for registered users only, public outlets were a mix of hospitals (five provided free insulin) and pharmacies, few private pharmacies and private hospitals/clinics dispense insulin so the number of public pharmacies sampled was increased; \*\*\*few hospitals dispense insulin so four primary healthcare outlets were added to the sample*

Table 2. Types of insulin

|  |  |  |
| --- | --- | --- |
| Short-acting | Human | Regular |
| Intermediate-acting | Human | Isophane, lente |
| Mixed Human | Human | Pre-mixed regular/isophane (eg. 30/70, 50/50) |
| Rapid-acting | Analogue | Aspart, lispro, glulisine |
| Long-acting | Analogue | Detemir, glargine, degludec |
| Mixed Analogue | Analogue | Pre-mixed aspart/protamine, lispro/protamine, aspart/degludec |
| Animal | Animal | Regular, isophane and mixed regular/isophane (porcine) |

Table 3. Median government procurement prices by insulin category, 10ml 100IU/ml in USD (any presentation)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Human insulin** | | | **Analogue insulin** | | |
| **Short-acting** | **Intermediate-acting** | **Mixed** | **Rapid-acting** | **Long-acting** | **Mixed** |
| **Overall median**  **(no. surveys; range)** | $4.56  (n=14;  $1.45-23.62) | $4.86  (n=10;  $1.45-24.72) | $5.30  (n=11;  $1.98-25.21) | $27.86  (n=5;  $27.02-38.18) | $33.36  (n=5;  $21.56-106.52) | $24.52  (n=3;  $24.39-27.90) |
| **Median originators**  **(no. surveys; range)** | $5.90  (n=9;  $2.38-26.51) | $5.90  (n=7;  $2.38-28.35) | $5.90  (n=7;  $2.38-28.35) | $27.44  (n=4;  $22.07-38.16) | $33.36  (n=5;  $21.56-106.52) | $24.52  (n=3;  $24.39-27.90) |
| **Median biosimilars (no. surveys; range)** | $3.55  (n=8;  $1.45-23.50) | $5.79  (n=6;  $1.45-24.23) | $3.55  (n=6;  $1.98-25.21) | $38.18  (n=1) | $79.78  (n=1) | - |